Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FABP3 | P05413 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115901 | 0.84 | MAPT (0.44) | MAPTMEN1KMT2ALMNARAB9A | |
| SCHEMBL2924883 | 0.84 | MAPT (0.44) | MAPTFABP3FABP4PBRM1POLB | |
| SCHEMBL2932570 | 0.83 | MAPT (0.42) | MAPTFABP3FABP4PBRM1POLB | |
| SCHEMBL13989934 | 0.83 | MEN1 (0.45) | MAPTFABP3FABP4PBRM1MEN1 | |
| SCHEMBL2931556 | 0.82 | MAPT (0.39) | MAPTFABP3FABP4POLBMEN1 | |
| SCHEMBL1116247 | 0.81 | MAPT (0.44) | MAPTFABP3FABP4PBRM1POLB | |
| SCHEMBL12856603 | 0.81 | MAPT (0.46) | MAPTFABP3FABP4PBRM1MEN1 | |
| SCHEMBL2925046 | 0.79 | MAPT (0.39) | MAPTFABP3FABP4PBRM1MEN1 | |
| SCHEMBL2927954 | 0.79 | MAPT (0.39) | MAPTPBRM1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2927096 | 0.79 | P2RX7 (0.41) | MAPTKMT2ALMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281819-A1 | Benzimidazolyl or benzoxazolyl derivatives | Novartis AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| EP-2281819-A1 | Benzimidazolyl or benzoxazolyl derivatives | Novartis AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090298824-A1 | Organic compounds | PRESS NEIL J | 2009-12-03 | — | — | US | disclosed |
| US-20090298824-A1 | Organic compounds | PRESS NEIL J | 2009-12-03 | — | — | US | disclosed |
| US-20090298824-A1 | Organic compounds | PRESS NEIL J | 2009-12-03 | — | — | US | disclosed |
| EP-1709015-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070906-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298824-A1 | Organic compounds | CXCR2, CXCR3, CXCR1 | MAPT 4012/4885FABP3 1991/4885FABP4 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.